Results 51 to 60 of about 75,992 (272)

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Journal for ImmunoTherapy of Cancer
Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of ...
David Liu, F Stephen Hodi, Rizwan Haq, Anita Giobbie-Hurder, Ann W Silk, Patrick A Ott, Tamara A Sussman, Elizabeth I Buchbinder, Anna K Maloney, Nikita Katukota, Miklos C Fogarasi, Megan Insco   +11 more
doaj   +1 more source

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Experimental Hematology & Oncology, 2018
Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.
Charles McCrea, Sukhvinder Johal, Shuo Yang, Justin Doan   +3 more
doaj   +1 more source

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment [PDF]

Clinical and Molecular Hepatology, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim   +12 more
doaj   +1 more source

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer, 2018
Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs).
Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh, Charles R. Thomas   +6 more
doaj   +1 more source

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data

, 2023
Yuntae Kim,1,2 Shun Yamamoto,1 Ken Kato1 1Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Gastroenterology, St.
Kato K, Yamamoto S, Kim Y
core  

A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
This study introduces a foundation model‐based biomarker for risk stratification of pathological response in non‐small cell lung cancer. A Vision Mamba super‐resolution model standardizes heterogeneous CT images. A multi‐task Swin Transformer then fine‐tunes a pre‐trained lung foundation model to jointly optimize tumor segmentation and response ...
Yanglan Xu, Shuchang Zhou, Qin Peng, Xiao Bao, Xiaodan Ye, Ahmet Görkem Er, Tong Tong, Mirabela Rusu, Yajia Gu, Mailin Chen, Jing Gong   +10 more
wiley   +1 more source

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Respiratory Medicine Case Reports, 2020
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018.
Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno   +9 more
doaj   +1 more source

Stromal Regulation of Tumor Perineural Invasion: A Multicellular and Neuro‐Ecological Perspective

Advanced Science, EarlyView.
This review reframes perineural invasion (PNI) as a dynamic, multicellular process within the tumor–nerve–stromal ecosystem. The authors delineate how cancer‐associated fibroblasts, Schwann cells, and immune cells remodel the neural niche to facilitate tumor spread.
Xiaoyang Lin, Yingqiao Liu, Haitao Lin, Kang Feng, Xiqiang Liu   +4 more
wiley   +1 more source

Enhancing Effector Jurkat Cell Activity and Increasing Cytotoxicity against A549 Cells Using Nivolumab as an Anti-PD-1 Agent Loaded on Gelatin Nanoparticles

Gels
The current research investigated the use of gelatin nanoparticles (GNPs) for enhancing the cytotoxic effects of nivolumab, an immune checkpoint inhibitor.
Dalia S. Ali, Heba A. Gad, Rania M. Hathout   +2 more
doaj   +1 more source